INSY - INSYS Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.9475
-0.0107 (-1.12%)
As of 11:48AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.9582
Open0.9526
Bid0.9428 x 1100
Ask0.9428 x 900
Day's Range0.9201 - 0.9996
52 Week Range0.8200 - 11.6500
Volume409,501
Avg. Volume1,160,937
Market Cap71.934M
Beta (3Y Monthly)3.03
PE Ratio (TTM)N/A
EPS (TTM)-3.0710
Earnings DateAug 6, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Trade prices are not sourced from all markets
  • Why Insys Therapeutics Fell More than 70% Yesterday
    Market Realist7 days ago

    Why Insys Therapeutics Fell More than 70% Yesterday

    Why Insys Therapeutics Fell More than 70% YesterdayLiquidity positionIn its first-quarter earnings press release, which it published on May 10, Insys Therapeutics (INSY) highlighted the possibility of its being unable to continue as a going concern.

  • Why Insys Therapeutics Stock Is Crashing Today
    Motley Fool8 days ago

    Why Insys Therapeutics Stock Is Crashing Today

    The biotech raised the possibility of filing for bankruptcy in its latest earnings report.

  • CNBC8 days ago

    Drugmaker Insys shares tank after saying opioid lawsuits may force it into bankruptcy

    A Boston jury convicted Insys founder John Kapoor and four former executives of racketeering and other crimes in a fentanyl bribery case that federal prosecutors say helped fuel the U.S. opioid epidemic. Insys Therapeutics INSY shares tanked Monday morning after the company said it may have to file for bankruptcy because it can't afford legal costs related to a Department of Justice investigation into the company's sales tactics of one of its popular opioids. Insys said it had $87.6 million in cash and cash equivalents at the end of March, which falls short of the $150 million tentative settlement the company made with the Department of Justice to settle claims that the company bribed doctors to unnecessarily prescribe its fentanyl-based drug Subsys, which is meant to treat cancer patients.

  • Opioid Maker Insys Plunges on Warning of Possible Bankruptcy
    Bloomberg8 days ago

    Opioid Maker Insys Plunges on Warning of Possible Bankruptcy

    “These factors raise substantial doubt about the company’s ability to continue as a going concern,” Insys said in a statement. Insys said last year Kapoor’s defense alone had cost the company $28 million so far.

  • Investing $1,000 Into This Marijuana Stock in 2016 Would Leave You With Pennies on the Dollar Today
    Motley Fool8 days ago

    Investing $1,000 Into This Marijuana Stock in 2016 Would Leave You With Pennies on the Dollar Today

    This once-promising pot stock may not survive the year.

  • Insys says it may be forced to file for bankruptcy due to litigation cash crunch
    Reuters10 days ago

    Insys says it may be forced to file for bankruptcy due to litigation cash crunch

    Insys Therapeutics Inc said on Friday that a cash crunch resulting from legal costs related to a U.S. Justice Department probe into sales practices for the company's powerful opioid medication and other litigation may lead the company to file for bankruptcy and prevent it from completing its settlement deal with the Justice Department. Insys, which has been exploring strategic options and is in talks to divest its opioid product Subsys, said it was likely that investors will lose all or a part of their investments if the company is not able to sell its assets at the value they are booked in its audited financial statements. Last August, Insys reached a tentative deal to pay at least $150 million to resolve a Department of Justice investigation into claims that the drugmaker paid doctors kickbacks to prescribe Subsys, an under-the-tongue spray that contains fentanyl, an opioid 100 times stronger than morphine.

  • Insys Therapeutics (INSY) Reports Q1 Loss, Lags Revenue Estimates
    Zacks11 days ago

    Insys Therapeutics (INSY) Reports Q1 Loss, Lags Revenue Estimates

    Insys Therapeutics (INSY) delivered earnings and revenue surprises of -323.08% and -48.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire11 days ago

    INSYS Therapeutics Reports First Quarter 2019 Results

    Company Continues to Execute Against Pipeline-Focused StrategyNew Drug Application Submitted for Proprietary Naloxone Nasal Spray FormulationCompany Provides Liquidity Update.

  • Market Exclusive18 days ago

    Insys Executives Found Guilty Of Bribing Doctors In Fentanyl Case

    John Kapoor and four other Insys Therapeutics Inc (NASDAQ:INSY) executives were found guilty of bribery in a racketeering case involving Fentanyl, the strongest opioid known to man. The jury presiding over the case came to a guilty verdict over the accusations presented against the Insys executives who include Kapoor, its founder and former director of […]The post Insys Executives Found Guilty Of Bribing Doctors In Fentanyl Case appeared first on Market Exclusive.

  • Bloomberg19 days ago

    Insys’s John Kapoor Is First CEO Convicted of Opioid Racketeering

    Federal jurors in Boston found that Kapoor conspired with four other executives to bribe doctors to pump up sales of Subsys and duped insurers into covering shady prescriptions. Former vice president Michael Gurry, ex-national sales director Richard Simon, former regional sales director Joseph Rowan, and one-time stripper turned Insys sales manager Sunrise Lee were also found guilty.

  • CNBC19 days ago

    Insys Therapeutics founder, former executives found guilty in criminal fentanyl bribery case

    A Boston jury convicted Insys Therapeutics founder John Kapoor and other former executives of racketeering and other crimes. Federal prosecutors say the fentanyl bribery case helped fuel the U.S. opioid epidemic. Prosecutors accused Kapoor and four former executives of bribing doctors to unnecessarily prescribe their painkiller, Subsys.

  • Ups and Downs in the Cannabis Space Last Week
    Market Realist22 days ago

    Ups and Downs in the Cannabis Space Last Week

    Cannabis Updates: Price Action, Ratings, and MoreCannabis spaceThe cannabis space was mostly positive last week. The Horizons Marijuana Life Sciences ETF (HMMJ) and the ETFMG Alternate Harvest ETF (MJ) gained 5.2% and 4.2%, respectively, while the

  • Cannabis Updates: New Listings, Price Action, and Ratings
    Market Realist29 days ago

    Cannabis Updates: New Listings, Price Action, and Ratings

    Cannabis Updates: New Listings, Price Action, and RatingsCannabis updateThe cannabis sector showed some weakness last week, and the Horizons Marijuana Life Sciences ETF (HMMJ) lost 3.0% while the ETFMG Alternate Harvest ETF (MJ) lost 3.4%.

  • GlobeNewswirelast month

    INSYS Therapeutics Implements Leadership Changes

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that the Board of Directors has appointed Andrew G. Long as Chief Executive Officer, effective immediately. Mr. Long succeeds Saeed Motahari, who has mutually agreed with the INSYS Board of Directors to resign as President and CEO of the Company. In connection with INSYS’ leadership changes, Andrece Housley, INSYS’ Corporate Controller, has been appointed Chief Financial Officer, succeeding Mr. Long.

  • 3 Marijuana Stocks to Avoid Like the Plague in April
    Motley Fool2 months ago

    3 Marijuana Stocks to Avoid Like the Plague in April

    Despite a blazing hot start to the year, these pot stocks look to be buzzkills.

  • Drug company founder, execs exploited patients to sell opioid: U.S. prosecutor
    Reuters2 months ago

    Drug company founder, execs exploited patients to sell opioid: U.S. prosecutor

    John Kapoor, the drugmaker's former chairman, and four colleagues are the first executives of a painkiller manufacturer to face trial for conduct that authorities say was tied to a drug abuse epidemic that kills tens of thousands of Americans each year. Kapoor was arrested in 2017 on the same day U.S. President Donald Trump declared the opioid crisis a public health emergency. Assistant U.S. Attorney Nathaniel Yeager told a federal jury in Boston in his closing argument that Kapoor sought to eliminate the risk of Insys failing after investing millions of dollars in founding it by bribing doctors to prescribe the company's pain drug Subsys.

  • These Worst-Performing Pot Stocks Fell at Least 20% in March
    Motley Fool2 months ago

    These Worst-Performing Pot Stocks Fell at Least 20% in March

    There are some very familiar marijuana stocks among this bunch of losers.

  • Implied Volatility Surging for INSYS Therapeutics (INSY) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for INSYS Therapeutics (INSY) Stock Options

    Investors need to pay close attention to INSYS Therapeutics (INSY) stock based on the movements in the options market lately.

  • Insys Therapeutics (INSY) Outpaces Stock Market Gains: What You Should Know
    Zacks2 months ago

    Insys Therapeutics (INSY) Outpaces Stock Market Gains: What You Should Know

    Insys Therapeutics (INSY) closed the most recent trading day at $4.62, moving +1.99% from the previous trading session.

  • GlobeNewswire2 months ago

    INSYS Therapeutics to Present Poster of Pharmacokinetic Study of Naloxone Novel Nasal Spray at The College on Problems of Drug Dependence Annual Scientific Meeting

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the Company will present a poster of its pharmacokinetic (PK) study of its novel naloxone nasal spray versus intravenous and intramuscular injection at the College on Problems of Drug Dependence (CPDD)’s 81st Annual Scientific Meeting in San Antonio, Texas on Monday, June 17, 2019 at 8:00am Central Time. A copy of the poster will be made available on the Company’s website following the presentation. INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life.

  • 3 Pot Stocks With Skyrocketing Short Interest
    Motley Fool2 months ago

    3 Pot Stocks With Skyrocketing Short Interest

    Pessimists are coming out of the woodwork as the green rush takes shape.

  • Insys Plunges on Auditor's Concern About Insufficient Funds
    Zacks2 months ago

    Insys Plunges on Auditor's Concern About Insufficient Funds

    Insys Therapeutics' (INSY) shares plunge after its auditor raises concerns related to insufficiency of funds to continue operations.